XERS Stock Overview
A biopharmaceutical company, engages in developing and commercializing therapies in Illinois.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.23 |
52 Week High | US$3.26 |
52 Week Low | US$1.46 |
Beta | 1.3 |
11 Month Change | 3.24% |
3 Month Change | 26.70% |
1 Year Change | -4.29% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -5.51% |
Recent News & Updates
Recent updates
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company
Jun 04Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Mar 30Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Mar 09Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 06Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth
Jan 05Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Shareholder Returns
XERS | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -8.2% | -2.4% | -5.7% |
1Y | -4.3% | 8.4% | 14.1% |
Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned 8.4% over the past year.
Return vs Market: XERS underperformed the US Market which returned 14.1% over the past year.
Price Volatility
XERS volatility | |
---|---|
XERS Average Weekly Movement | 8.8% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XERS has not had significant price volatility in the past 3 months.
Volatility Over Time: XERS's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 377 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
XERS fundamental statistics | |
---|---|
Market cap | US$315.78m |
Earnings (TTM) | -US$64.40m |
Revenue (TTM) | US$171.36m |
1.9x
P/S Ratio-5.1x
P/E RatioIs XERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XERS income statement (TTM) | |
---|---|
Revenue | US$171.36m |
Cost of Revenue | US$29.30m |
Gross Profit | US$142.06m |
Other Expenses | US$206.46m |
Earnings | -US$64.40m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.43 |
Gross Margin | 82.90% |
Net Profit Margin | -37.58% |
Debt/Equity Ratio | -2,502.4% |
How did XERS perform over the long term?
See historical performance and comparison